Wang et al., 2024 - Google Patents
Casein nanoparticles as oral delivery carriers for improved bioavailability and hypoglycemic activity of apigenin.Wang et al., 2024
- Document ID
- 17401366133315284026
- Author
- Wang L
- Jia W
- Yang Q
- Cai H
- Zhao X
- Publication year
- Publication venue
- Food Hydrocolloids
External Links
Snippet
Apigenin (AP) has been reported with several pharmacological effects such as, antioxidant, anti-inflammatory, anticancer and antidiabetic. Due to low solubility and bioavailability, apigenin has not been widely used in clinical practice. Casein has been widely used as the …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/30—Macromolecular compounds
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin, zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48961—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the conjugate being in the form of a host-guest, i.e. being an inclusion complex, e.g. clathrate, cavitate, fullerene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | The hydrogel of whey protein isolate coated by lotus root amylopectin enhance the stability and bioavailability of quercetin | |
Zhou et al. | Chitosan-coated liposomes as delivery systems for improving the stability and oral bioavailability of acteoside | |
Kandemir et al. | Recent advances on the improvement of quercetin bioavailability | |
Liu et al. | Zein/fucoidan-based composite nanoparticles for the encapsulation of pterostilbene: Preparation, characterization, physicochemical stability, and formation mechanism | |
Liu et al. | Encapsulation and sustained release of curcumin by a composite hydrogel of lotus root amylopectin and chitosan | |
Huang et al. | Preparation of inclusion complex of apigenin-hydroxypropyl-β-cyclodextrin by using supercritical antisolvent process for dissolution and bioavailability enhancement | |
Feng et al. | Structural characterization and bioavailability of ternary nanoparticles consisting of amylose, α-linoleic acid and β-lactoglobulin complexed with naringin | |
Meng et al. | Konjac glucomannan octenyl succinate as a novel encapsulation wall material to improve curcumin stability and bioavailability | |
Wang et al. | Self-assembled amphiphilic chitosan nanomicelles to enhance the solubility of quercetin for efficient delivery | |
Sun et al. | Fabrication and characterization of dihydromyricetin encapsulated zein-caseinate nanoparticles and its bioavailability in rat | |
Wang et al. | Casein nanoparticles as oral delivery carriers for improved bioavailability and hypoglycemic activity of apigenin. | |
Nguyen et al. | Cost-effective alternative to nano-encapsulation: amorphous curcumin–chitosan nanoparticle complex exhibiting high payload and supersaturation generation | |
Li et al. | Synthesis and study the properties of StNPs/gum nanoparticles for salvianolic acid B-oral delivery system | |
Safavi et al. | Reducing agent-free synthesis of curcumin-loaded albumin nanoparticles by self-assembly at room temperature | |
Sheng et al. | Preparation of quercetin nanorod/microcrystalline cellulose formulation via fluid bed coating crystallization for dissolution enhancement | |
CN114641317A (en) | 7, 8-dihydroxyflavone composite nano biomaterial with high bioavailability as well as preparation method and application thereof | |
Hoang et al. | Novel drug delivery system based on ginsenoside Rb1 loaded to chitosan/alginate nanocomposite films | |
Tian et al. | Fabrication of nanosuspensions to improve the oral bioavailability of total flavones from Hippophae rhamnoides L. and their comparison with an inclusion complex | |
Lu et al. | Improving quercetin dissolution and bioaccessibility with reduced crystallite sizes through media milling technique | |
Liu et al. | Nanoparticles prepared by polysaccharides extracted from Biyang floral mushroom loaded with resveratrol: Characterization, bioactivity and release behavior under in vitro digestion | |
Wu et al. | Fabrication and characterization of zein-sodium alginate complex nanoparticles as an effective naringenin delivery system: physicochemical stability, solubility, antioxidant activity | |
Liu et al. | Coordinated encapsulation by β-cyclodextrin and chitosan derivatives improves the stability of anthocyanins | |
CN107049944B (en) | Polymer micelle capable of realizing simultaneous administration of sorafenib and curcumin and preparation method thereof | |
Tran et al. | A new solubility enhancement strategy of capsaicin in the form of high-payload submicron capsaicin-chitosan colloidal complex | |
Wang et al. | Fabrication of hesperetin/hydroxypropyl-β-cyclodextrin complex nanoparticles for enhancement of bioactivity using supercritical antisolvent technology |